BACKGROUND OBJECTIVES

METHODS
RESULTS
Research Design: Implementation of the PDL provided a natural time series experiment. We obtained Arkansas Medicaid claims data from January 1999 to July 2007. Subjects: Our sample included recipients eligible for at least 1 month from January 2003 to July 2007 and excluded recipients not subject to the PDL (Medicare dual eligibles, tuberculosis patients, long term care patients, cancer patients, and patient who cannot take oral medications). Measures: Net costs for long acting narcotics were calculated by applying rebated discount percentages to the claim paid amounts. Utilization measures for narcotics were morphine equivalents, days supply, and prescription counts. Milligrams of morphine equivalents (mgME) were calculated from standardized conversion tables. The utilization measure for non-narcotic substitutes was prescription counts. Statistical Analysis: Autoregressive integrated moving average (ARIMA) time series models of aggregate monthly narcotic cost and utilization measures were generated to forecast the post policy measures based on the 33 month prepolicy trends. The impact of the policy was estimated by taking the difference between forecast and observed measures after the PDL where negative values indicate a savings for measures of expenditure or a reduction in utilization for utilization measures. Interrupted ordinary least squares regression (OLS) time series models were also estimated to capture the impact of the policy on the shifts in trend and intercept. OLS models were the primary analysis for non-narcotic substitutes. Sensitivity analyses modeled the impact of generic fentanyl availability 8 months prior to the PDL, PMPM metrics, and including extended-release tramadol for narcotic measures. Impact of the LANA PDL on Expenditures of Narcotics There were 709,791 subjects with at least one month of eligibility for pharmacy benefits. 3,227 had at least one prescription for a LANA. Total net costs for LANA were $1.40 million ($0.29 PMPM) the year prior to the policy and were $0.37 million ($0.07 PMPM) after the policy. The PDL was associated with a -$1.41 million (95%CI: -$0.37 to -$2.43 million) or PMPY -$1.79 (95%CI: -$0.28 to -$3.30) difference in LANA costs and a -$1.78 million (95%CI: -$0.48 to -$3.05 million) or PMPY -$0.57 (95%CI: -$2.06 to $0.92) difference across all narcotic analgesics over the 22 month post policy period.
LIMITATIONS & CONCLUSIONS
Impact of the LANA PDL on Utilization of Narcotics Post PDL total narcotic utilization was not significantly different from trend utilization; average monthly difference of -434,553 mgME (95%CI -1,778,375 to 909,269 mgME) or average PMPM -0.26 mgME (95%CI: -3.65 to 3.12 mgME). The PDL was associated with a significant increase in average monthly schedule II short acting narcotic utilization of 202,828 mgME (95%CI: 68,160 to 337,497 mgME) or average PMPM 0.51 mgME (95%CI 0.12 to 0.90 mgME) and non-significant decreases in schedule II LANA and schedule III-V narcotic utilization.
Impact of the LANA PDL on Utilization of Non-Narcotic Substitutes
The results of our OLS time series analysis of non-narcotic substitutes showed no policy-associated increase in the prescription counts for the following potential substitute drugs: anticonvulsants, benzodiazepines, muscle relaxants, COX-2 NSAIDS, non-selective NSAIDS, SNRI, SSRI, TCA, triptans, or miscellaneous analgesics. However, in an a priori model that included pregabalin, utilization of selected anticonvulsants appeared to have increased co-incident with the PDL policy.
Sensitivity Analysis
A sensitivity analysis that utilized alternative ARIMA forecast model specifications including a deterministic term to capture the effect of generic fentanyl availability 8 months prior to the PDL yielded more conservative cost reduction estimates for LANA of -$0.88 million (95%CI: -$0.66 to -$1.10 million) or PMPY -$0.80 (95%CI -$0.49 to -$1.10). Cost reductions for total narcotics were nonsignificant when summed over the 22-month post policy: -$0.13 million (95%CI: -0.53 to 0.28 million) or PMPY -$0.40 (95%CI -$1.02 to $0.23). There were no major changes in interpretation with the inclusion of extended-release tramadol in the analyses.
Limitations:
We explored alternative time series model specifications and there were meaningful differences in the savings estimates derived from each. It is impossible to know the correct model specification with certainty; however, we feel that the base model is the more likely because 85% of the prescriptions issued for transdermal fentanyl were for the generic product the month before the policy. The fentanyl model, which assumes an increasing savings with generic fentanyl, is unlikely given that the majority of the savings of generic fentanyl were realized before the policy. In addition, MAC pricing for fentanyl was initiated 11 days before the PDL. Since we excluded persons not subject to the PDL, the effect of the MAC pricing policy on our estimates would be minimal.
Conclusions:
The PDL resulted in significant cost savings for LANA and total narcotics of over $1.4 million U.S. The total analgesia, as measured by total narcotic morphine equivalents, made available to the Arkansas Medicaid population appears to have been unaffected by this policy. It appears there may have been a transient decrease in prescribed morphine equivalents for LANA and an increase in C-II SANA morphine equivalents suggesting that short acting C-IIs may have been used as substitutes for LANA for some recipients. Non-narcotic substitute utilization was unaffected by the policy. Among the preferred agents, there was a greater increase in the utilization of extended release morphine than methadone. A Natural Experiment To Estimate The Impact Of A Preferred Drug A Natural Experiment To Estimate The Impact Of A Preferred Drug List Policy List Policy For Long Acting Narcotic Analgesics On Costs And Utilization For Long Acting Narcotic Analgesics On Costs And Utilization OBJECTIVES
